Retatrutide: Release Date, Expected Magnitude, and What to Watch
The most-anticipated obesity medication of the late 2020s. Here's what we know about the Phase 3 program, expected timeline to approval, what Phase 2 results suggest about clinical magnitude, and what's worth watching.
The 60-second version
Retatrutide is Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist. Phase 2 showed approximately 24% mean weight loss at 48 weeks — deeper than tirzepatide. Phase 3 TRIUMPH program ongoing with readouts through 2026; FDA approval likely 2026-2027. Mechanism adds glucagon receptor agonism to tirzepatide's dual GIP/GLP-1 — additional weight loss through energy expenditure and direct hepatic effects, balanced against tolerability challenges. If approved, retatrutide becomes the deepest available weight-loss agent.
Key takeaways
- Retatrutide is Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist.
- Phase 2 produced 24.2% mean weight loss at 48 weeks at the 12 mg dose.
- Phase 3 TRIUMPH readouts staggered through 2024-2026.
- FDA approval likely late 2026 to 2027.
- Will likely become the deepest available weight-loss agent if approved.
- Glucagon arm adds energy expenditure and direct hepatic effects beyond GIP/GLP-1.
- Possible NAFLD/MASH indication beyond pure weight loss.
- Expected pricing similar to tirzepatide.
The mechanism: triple agonism
Retatrutide activates three receptors simultaneously: GLP-1 (appetite, gastric emptying — foundation of the class), GIP (adipose tissue effects, complementary insulin biology — same as tirzepatide), glucagon (energy expenditure raising metabolic rate, direct hepatic effects reducing liver fat). Glucagon arm is the new addition. Glucagon raises blood sugar but also increases energy expenditure and produces hepatic effects beneficial for NAFLD/MASH. Retatrutide's design balances these arms.
Phase 2 data: 24% weight loss at 48 weeks
Jastreboff et al., NEJM 2023. Mean weight loss at 48 weeks at 12 mg dose: 24.2%. Higher than tirzepatide (21% at 72 weeks) and semaglutide (15% at 68 weeks). Acceptable safety profile in Phase 2 (GI side effects predominantly). For context: approaches what bariatric surgery often produces. Pharmacological obesity treatment reaching surgical-magnitude weight loss is genuinely transformative.
Phase 2-to-Phase 3 translation isn't guaranteed. Some compounds show smaller magnitudes in Phase 3. Realistic Phase 3 expectations: 20-25% mean weight loss at extended timepoints.
The TRIUMPH Phase 3 program
TRIUMPH 1: Obesity without diabetes (largest population). TRIUMPH 2: Obesity with diabetes. TRIUMPH 3: Various subpopulations. TRIUMPH Outcomes: Cardiovascular outcomes trial. Readouts began 2024 with continued staggered releases through 2026. TRIUMPH 1 obesity-without-diabetes primary readout is the most-watched data point.
When approval might happen
Primary Phase 3 readouts: 2024-2026 (staggered). NDA submission: 6-12 months after positive readouts. FDA review: 10-12 months for new molecular entities. Expected approval: late 2026 to 2027, with possible extension into 2028. Eli Lilly has manufacturing capacity and commercial infrastructure to launch quickly.
What approval would mean
Deepest available weight-loss agent. Natural step beyond tirzepatide for patients who plateau on dual agonism. Likely first-line for severe obesity (BMI >40 or significant comorbidities). Pricing comparable to tirzepatide ($1,000-1,500/month at cash). Pressure on existing products. Possible NAFLD/MASH indication — glucagon arm contributes to direct hepatic fat reduction.
What's worth watching
Magnitude of weight loss in Phase 3 vs. Phase 2 — does 24% hold or scale down? Side effect profile at scale, particularly tolerability of glucagon arm and any glycemic concerns. Cardiovascular outcomes — TRIUMPH outcomes trial. NAFLD-specific data — does retatrutide warrant a NASH/MASH indication? Population-specific effects in older adults, diabetes, comorbidities. Long-term durability — does weight loss sustain over 1-2 years or is there regain?
The bigger picture
Retatrutide is the leading example of a generational pattern: each successive obesity medication generation has added approximately 5-10 percentage points over its predecessor. Semaglutide (15%), tirzepatide (21%), retatrutide (24%) — and likely more in subsequent generations. The class has transformed obesity treatment expectations within a 5-year window. By the late 2020s, treatment will look fundamentally different from 2017.
Frequently asked questions
When can I actually get retatrutide?
Pending FDA approval, expected late 2026 to 2027. Currently only through clinical trials.
Will retatrutide replace tirzepatide?
Partially. For maximum weight loss, retatrutide will likely become preferred. For other contexts, tirzepatide and semaglutide remain widely used.
How is retatrutide different from tirzepatide?
Adds glucagon receptor activation. Third receptor arm contributes energy expenditure and hepatic effects.
Should I switch when it's available?
Depends on your situation. If tolerating tirzepatide well and meeting goals, no urgent reason. If plateaued or want deeper effect, retatrutide becomes worth considering.
Will it be available in compounded form?
Probably not, given post-2024 FDA actions on compounding. Initial launch will be brand-name only.
Does retatrutide have cardiovascular outcomes data?
TRIUMPH outcomes trial is part of Phase 3. Expected positive based on class trajectory; specific results not yet published.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
- Rosenstock J, et al. Retatrutide in type 2 diabetes: Phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/?term=retatrutide+phase+2+diabetes
We update articles as new trials publish and the evidence base evolves. Last reviewed: May 2026.